Antisense oligonucleotide therapy for neurodegenerative disease

Journal of Clinical Investigation

Volumn 116, Issue 8, 2006, Pages 2290-2296

  Smith, Richard A ^a,b,c   Miller, Timothy M ^a,d   Yamanaka, Koji ^a   Monia, Brett P ^e   Condon, Thomas P ^e   Hung, Gene ^e   Lobsiger, Christian S ^a   Ward, Chris M ^a   McAlonis Downes, Melissa ^a   Wei, Hongbing ^e   Wancewicz, Ed V ^e   Bennett, C Frank ^e   Cleveland, Don W ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c The Center for Neurologic Study   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BRAIN PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; MUTANT PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DOWN REGULATION; DRUG SCREENING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; RAT;

ANIMALS; BASE SEQUENCE; FIBROBLASTS; HEART VENTRICLES; MACACA MULATTA; MOTOR NEURON DISEASE; NEURODEGENERATIVE DISEASES; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN FOLDING; RATS; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 33746667851     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25424     Document Type: Article

References (56)

1. Bossy-Wetzel, E., Schwarzenbacher, R., and Lipton, S.A. 2004. Molecular pathways to neurodegeneration. Nat. Med. 10(Suppl.):S2-S9.
2. Xia, H., Mao, Q., Paulson, H.L., and Davidson, B.L. 2002. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20:1006-1010.
3. Xia, H., et al. 2004. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10:816-820.
4. Singer, O., et al. 2005. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 8:1343-1349.
5. Raoul, C., et al. 2005. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11:423-428.
6. Miller, T.M., et al. 2005. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57:773-776.
7. Ralph, G.S., et al. 2005. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11:429-433.
8. Harper, S.Q., et al. 2005. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102:5820-5825.
9. Crooke, S.T. 2004. Progress in antisense technology. Annu. Rev. Med. 55:61-95.
10. Fishman, R.A. 1992. Cerebrospinal fluid in diseases of the nervous system. Saunders. Philadelphia, Pennsylvania, USA. 431 pp.
11. Dash, A.K., and Cudworth, G.C., 2nd. 1998. Therapeutic applications of implantable drug delivery systems. J. Pharmacol. Toxicol. Methods. 40:1-12.
12. North, R.B., and Levy, R.M. 1997. Neurosurgical management of pain. Springer. New York, New York, USA. 360 pp.
13. McKay, R.A., et al. 1999. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J. Biol. Chem. 274:1715-1722.
14. Zhang, H., et al. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18:862-867.
15. Cook, P.D. 1998. Second generation antisense oligonucleotides: 2′-modifications. Annu. Rep. Med. Chem. 33:313-325.
16. Goodman, L.S., Hardman, J.G., Limbird, L.E., and Gilman, A.G. 2001. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill. New York, New York, USA. 2148 pp.
17. Butler, M., Stecker, K., and Bennett, C.F. 1997. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77:379-388.
18. Pardo, C.A., et al. 1995. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc. Natl. Acad. Sci. U. S. A. 92:954-958.
19. Rosen, D.R., et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:59-62.
20. Broaddus, W.C., Prabhu, S.S., Wu-Pong, S., Gillies, G.T., and Fillmore, H. 2000. Strategies for the design and delivery of antisense oligonucleotides in central nervous system. Methods Enzymol. 314:121-135.
21. Cossum, P.A., et al. 1993. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267:1181-1190.
22. Borchelt, D.R., et al. 1994. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. U. S. A. 91:8292-8296.
23. Thinakaran, G., et al. 1996. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 117:181-190.
24. Lucas, J.J., et al. 2001. Decreased nuclear betacatenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:27-39.
25. Noble, W., et al. 2005. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:6990-6995.
26. Phiel, C.J., Wilson, C.A., Lee, V.M., and Klein, P.S. 2003. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 423:435-439.
27. Howland, D.S., et al. 2002. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 99:1604-1609.
28. Liu, J., Shinobu, L.A., Ward, C.M., Young, D., and Cleveland, D.W. 2005. Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J. Neurochem. 93:875-882.
29. Azzouz, M., et al. 2004. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 429:413-417.
30. Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D., and Gage, F.H. 2003. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 301:839-842.
31. Dykxhoorn, D.M., Novina, C.D., and Sharp, P.A. 2003. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4:457-467.
32. Crooke, S.T. 2004. Antisense strategies. Curr. Mol. Med. 4:465-487.
33. Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P. 2000. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 101:25-33.
34. Dorn, G., et al. 2004. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32:1-6.
35. Grimm, D., et al. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 441:537-541.
36. Clement, A.M., et al. 2003. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 302:113-117.
37. Subramaniam, J.R., et al. 2002. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. 5:301-307.
38. Reaume, A.G., et al. 1996. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13:43-47.
39. Bruijn, L.I., et al. 1998. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 281:1851-1854.
40. Cudkowicz, M.E., et al. 1997. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 41:210-221.
41. Price, D.L., and Sisodia, S.S. 1998. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:479-505.
42. Potempska, A., Styles, J., Mehta, P., Kim, K.S., and Miller, D.L. 1991. Purification and tissue level of the beta-amyloid peptide precursor of rat brain. J. Biol. Chem. 266:8464-8469.
43. Cleveland, D.W., Hwo, S.Y., and Kirschner, M.W. 1977. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116:207-225.
44. Iwai, A., et al. 1995. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:467-475.
45. Zheng, H., et al. 1995. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 81:525-531.
46. Cai, H., et al. 2001. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4:233-234.
47. Harada, A., et al. 1994. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 369:488-491.
48. Zeitlin, S., Liu, J.P., Chapman, D.L., Papaioannou, V.E., and Efstratiadis, A. 1995. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11:155-163.
49. Nasir, J., et al. 1995. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81:811-823.
50. Taylor, J.P., Hardy, J., and Fischbeck, K.H. 2002. Toxic proteins in neurodegenerative disease. Science. 296:1991-1995.
51. Cheruvallath, Z.S., Kumar, R.K., Rentel, C., Cole, D.L., and Ravikumar, V.T. 2003. Solid phase synthesis of phosphorothioate oligonucleotides utilizing diethyldithiocarbonate disulfide (DDD) as an efficient sulfur transfer reagent. Nucleosides Nucleotides Nucleic Acids. 22:461-468.
52. Drygin, D., Barone, S., and Bennett, C.F. 2004. Sequence-dependent cytotoxicity of second-generation oligonucleotides. Nucleic Acids Res. 32:6585-6594.
53. Drygin, D., Koo, S., Perera, R., Barone, S., and Bennett, C.F. 2005. Induction of toll-like receptors and NALP/PAN/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cells. Oligonucleotides. 15:105-118.
54. Winer, J., Jung, C.K., Shackel, I., and Williams, P.M. 1999. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270:41-49.
55. Leeds, J.M., Graham, M.J., Truong, L., and Cummins, L.L. 1996. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235:36-43.
56. Geary, R.S., et al. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12:383-393.